© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Cefuroxime falls into the group of second-generation cephalosporin antibiotics. It handles a range of bacterial infections, but understanding the raw material behind it means digging into the details. Cefuroxime Acid, the non-esterified form, plays a central part in the synthesis and formulation of finished antibiotic drugs. The two substances share a core molecular foundation, yet chemical form and physical traits set them apart. The chemical formula for Cefuroxime stands at C16H16N4O8S, while Cefuroxime Acid points to the presence of a free acid group that impacts its behavior in solutions and its handling during manufacturing. On the regulatory front, the Harmonized System (HS) Code for Cefuroxime identifies the compound in global trade, usually cataloged under 2941.90, which covers antibiotics and their derivatives.
Both Cefuroxime and Cefuroxime Acid hold a complex β-lactam ring structure fused to a dihydrothiazine ring, which is responsible for their action against bacterial cell wall synthesis. Their specifications cover parameters like purity, solubility, melting point, and polymorphic form. In my experience with chemical raw materials, the smallest deviation in these specs can have huge downstream impacts in pharmaceutical manufacturing quality control. Cefuroxime Acid’s physical form usually arrives as a fine powder, which makes handling simple in most production settings. The crystalline nature of the acid form creates a stark white or slightly off-white appearance, standing out from more opaque pharmaceutical intermediates. Density for these solids drifts around 1.65 to 1.8 g/cm³; though this might look academic, in bulk shipping or high-volume mixing, every decimal matters for dosing precision and equipment calibration.
The molecular nature of Cefuroxime and Cefuroxime Acid means they carry moderate stability but remain sensitive to strong acids or bases—something that anyone handling them needs to consider during storage. Their solid forms break down into a fine, almost floury powder or sometimes form thin, flat flakes depending on the crystallization technique, with the powder benefiting bulk handling and flakes favored in smaller-scale, specialty compounding. Crystal formation in these raw materials forms the basis for pharmaceutical purification; only a clean, well-defined lattice brings purity above the 98% threshold demanded by drug makers. Solutions made from either raw material require careful pH adjustment—the acid form dissolves best in water adjusted to neutral or slightly alkaline pH, never blindly trusting standard dilution guides. Clarity in a Cefuroxime solution reveals much about purity and presence of unreacted material or aggressive solvents.
Cefuroxime and Cefuroxime Acid turn up as powder, flakes, solid crystals, and now and then, micro-pearls for controlled release applications. The liquid form appears only as a prepared solution, with concentration ranging from 5 mg/ml up to 100 mg/ml, depending on intended use. Anyone storing these chemicals in bulk faces the risk of caking or moisture ingress, which can spoil entire batches. Air-tight, light-resistant containers cut down on degradation, as both are somewhat light-sensitive. For laboratory-scale use, weighing and dissolving Cefuroxime Acid works out fast, but mistakes in calculation—based on density or volume—can shoot final yields off course, especially where precision is everything to avoid overdose or weak products in clinical settings.
Both substances are classed as hazardous chemicals in most jurisdictions. Cefuroxime Acid can irritate the skin, eyes, and respiratory system, and though toxicity remains low compared to more corrosive industrial chemicals, careless exposure risks allergic reactions in sensitized people. Direct contact sometimes leads to rashes, sneezing, or in rare cases, more severe immune responses. It’s important to emphasize the risk of antibiotic resistance: careless disposal or environmental release allows fragments of these compounds to foster stronger bacterial populations—a threat closely watched by health authorities. Gloves, masks, and ventilated workspaces cut down on accidental exposure anytime these raw materials come out. Spills require immediate cleanup with wet methods and proper chemical neutralization, since dust from antibiotic powders travels fast.
Beyond their clinical role, these raw materials support every link in the pharmaceutical supply chain. Tight control of material purity and polymorphic consistency means the finished product passes regulatory muster and, most importantly, does its job in the patient without unexpected toxicity or under-dosing. Incorrect particle size can change how quickly a tablet dissolves or how stable a liquid form stays over time. In my years talking with formulation scientists, nearly every problem in finished antibiotics tracks back to a raw material oversight—out-of-spec density, lower crystal clarity, or trace solvent residues. Solutions include more robust supplier qualification, using real-time spectroscopy to catch purity drifts, and close collaboration with trusted sources for documentation. No batch gets out the door safely without a dense bank of property data: melting point in the 151-156°C range, density checks every lot, and ongoing screening for trace metals or solvent residues.
